CTH 401
Alternative Names: CTH-401Latest Information Update: 19 Aug 2025
At a glance
- Originator Cartherics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Endometriosis; Ovarian cancer; Solid tumours
Most Recent Events
- 19 Aug 2025 Preclinical trials in Endometriosis in Australia (Parenteral) (Cartherics pipeline, August 2025)
- 19 Aug 2025 Cartherics plans a pre-IND meeting with the US FDA in 2027 (Cartherics pipeline, August 2027)
- 30 Sep 2024 Cartherics plans phase I trial for Ovarian cancer in 2027 (Parenteral) (Cartherics pipeline, August 2025)